The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, and Republicans expanding their majority in the Senate. Will there be bipartisan collaboration or political conflict and policy immobilism? This paper provides a detailed analysis why the US pharma industry, specifically targeting the high cost of prescription drugs, will be the number one focus for politicians. This paper outlines future pharmaceutical public policies that could be forthcoming where bipartisan agreement can be reached and what specific pharma company business policy steps can be taken in response to potential policies affecting the industry.
Contact us at insights@axtria.com with any questions.